Global Lung Cancer Screening Software Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Lung Cancer Screening Software Market Analysis

The lung cancer screening software market is experiencing significant growth due to advancements in AI-powered diagnostic tools and the rising need for early detection of lung cancer. The increasing adoption of low-dose CT scans, combined with software that enhances imaging accuracy, is improving diagnostic workflows and reducing false positives. Key developments include integration with cloud-based platforms for data management and real-time analytics, enabling healthcare providers to track patient data more effectively. Regulatory support, such as the FDA's approval of AI-driven screening tools, further drives market expansion. In addition, the growing prevalence of lung cancer globally and increasing awareness of early screening programs are fueling demand for advanced screening software solutions.

Lung Cancer Screening Software Market Size

The global lung cancer screening software market size was valued at USD 39.69 billion in 2023 and is projected to reach USD 163.98 billion by 2031, with a CAGR of 19.40% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Lung Cancer Screening Software Market Trends

“Increasing Integration of Artificial Intelligence (Ai) into Screening Solutions”

The lung cancer screening software market is experiencing significant growth, driven by increasing demand for advanced diagnostic tools and early detection technologies. A key trend shaping the market is the integration of artificial intelligence (AI) into screening solutions, enhancing accuracy and efficiency in detecting lung nodules. For instance, companies such as Thynk Health, in collaboration with Infervision, have integrated AI to improve pulmonary nodule management, enabling faster diagnosis and better patient outcomes. This trend is accelerating adoption, particularly in regions with high lung cancer prevalence. AI-powered software solutions streamlines workflows and reduce false positives, making lung cancer screening more reliable. As healthcare providers continue to invest in cutting-edge technology, the demand for lung cancer screening software is set to rise, further propelled by initiatives like the joint effort of Aidence, Incepto, and Thirona in expanding screening programs across Europe.

Report Scope and Lung Cancer Screening Software Market Segmentation         

Lung Cancer Screening Software Market Definition

Lung cancer screening software is a specialized diagnostic tool designed to assist healthcare professionals in detecting and managing lung cancer at an early stage. It integrates advanced technologies such as artificial intelligence (AI) and computer-aided detection (CAD) to analyze medical images, including CT scans and chest radiographs, for identifying lung nodules or abnormalities. The software enhances accuracy, improves workflow efficiency, and reduces false-positive results, making it a vital component in screening programs. By facilitating early detection, lung cancer screening software plays a crucial role in improving patient outcomes and supporting timely interventions in lung cancer care.

Lung Cancer Screening Software Market Dynamics

Drivers

• Rising Incidence of Lung Cancer

The rising incidence of lung cancer is significantly driving the demand for effective treatment options, with 10 million cancer death cases in 2022 or nearly one in six deaths , according to the World Health Organization (WHO). Such increasing prevalence is attributed to factors including smoking, environmental pollution, and occupational exposure to carcinogens. In response, there is a growing demand for more advanced treatments, including targeted therapies, immunotherapies, and precision medicine. For instance, drugs targeting genetic mutations such as EGFR, ALK, and KRAS have become essential in personalized treatment plans, improving patient outcomes. This surge in innovative treatment development is emerging as a critical market driver, propelling the growth of the lung cancer therapeutics sector.

• Enhancing Lung Cancer Screening Efficiency

Enhanced lung cancer screening efficiency has been significantly bolstered by technological advancements in imaging, particularly with the widespread use of low-dose CT (LDCT) scans. Studies show that LDCT can reduce lung cancer mortality by up to 20% compared to traditional chest X-rays, according to the National Lung Screening Trial (NLST). These imaging technologies enable earlier detection of lung cancer, often at a more treatable stage, by providing detailed cross-sectional images of lung tissues. Such innovations in imaging are driving increased adoption of screening programs globally, propelling lung cancer screening software market growth.

Opportunities

• Rising Trend of Telemedicine in Remote Areas

The rising trend of telemedicine in remote areas is transforming healthcare access and delivery, addressing significant gaps in medical services. According to a 2023 report by the World Health Organization, over 4.5 billion people globally lack access to essential health services, with many residing in rural and underserved regions. Telemedicine has emerged as a viable solution, allowing patients to consult healthcare providers through video calls, phone consultations, and mobile health applications, thereby eliminating geographical barriers. In addition, initiatives such as the U.S. Federal Communications Commission's Rural Health Care Program have expanded broadband access, further facilitating telehealth services. Such trend enhances patient engagement and reduces healthcare costs, ultimately creating numerous opportunities in the market.

• Enhancing Diagnostics through Multimodal Imaging Integration

Enhanced diagnostics through the integration of multimodal imaging are revolutionizing the approach to disease detection and management. Multimodal imaging combines various imaging modalities, such as positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT), to provide a more comprehensive view of patient health. For instance, a study published in the National Library of Medicine highlights that combining PET and CT imaging significantly improves the accuracy of lung cancer staging, with an accuracy rate of 86% to 90% compared to standalone imaging techniques. Such integration aids in precise tumor characterization and enhances treatment planning and monitoring, enabling clinicians to tailor interventions to individual patient needs. This growing trend presents a significant market opportunity, as healthcare providers increasingly adopt multimodal imaging technologies to improve diagnostic outcomes.

Restraints/Challenges

• Challenges Arising From Regulatory Evolution

The stringent and ever-evolving regulations surrounding healthcare software, particularly in lung cancer screening, create significant barriers for companies attempting to enter the market. Compliance requires rigorous testing, validation, and approval processes, which extend timelines for product development and market launch. Such regulatory demands can result in substantial delays for companies, affecting their ability to introduce new screening software effectively. As a consequence, such challenges may impede growth and hinder innovation within the global lung cancer screening software market, ultimately limiting the availability of advanced diagnostic tools that are crucial for early detection and improved patient outcomes in lung cancer management.

• Overuse of Nasal Sprays

The substantial financial investment needed to integrate advanced lung cancer screening software into existing healthcare systems poses a significant challenge for hospitals and healthcare providers, particularly in regions with limited budgets. For instance, a small rural hospital may face costs exceeding a million USD to implement a comprehensive lung cancer screening program that includes software, training, and necessary hardware upgrades. Such financial burden can deter decision-makers from adopting innovative solutions, leading to delays in implementing essential screening technologies. Consequently, the inability to seamlessly incorporate these advanced lung cancer screening solutions restricts access to early detection and improved patient outcomes and hinders the overall growth of the market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Lung Cancer Screening Software Market Scope

The market is segmented on the basis of mode of delivery, product, type, application, platform, purchase mode, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Mode of Delivery

• Cloud Based Solutions
• On-Premise Solutions
• Web Based Solutions

Product

• Lung Cancer Screening Radiology Solution
• Lung Cancer Screening Patient Management Software
•  Nodule Management Software
•  Data Collection and Reporting
•  Patient Coordination and Workflow
•  Lung Nodule Computer Aided Detection
•  Pathology and Cancer Staging
•  Statistical Audit Reporting
•  Screening PACS
•  Practice Management
•  Audit Log Tracking

Type

• Computer-Assisted Screening
•  Traditional Screening

Application

• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

Platform

• Standalone
• Integrated

Purchase Mode

• Institutional
• Individual

End User

• Oncology Centers
• Hospitals
• Ambulatory Surgical Centers
• Others

Distribution Channel

• Direct Tender
• Third Party Distributors

Lung Cancer Screening Software Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, mode of delivery, product, type, application, platform, purchase mode, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is anticipated to lead the market and witness significant growth, propelled by several crucial factors. These include the expansion of screening programs, growing adoption of software solutions for efficient patient management, increased demand for screening through chest radiography, and the strong presence of numerous screening centers. Together, these elements highlight North America's dominance in the lung cancer screening software market, underscoring its key role in shaping the industry's future.

Asia-Pacific is expected to be the fastest-growing region in the global lung cancer screening software market. Such growth is driven by a combination of factors, including the increasing incidence of lung cancer, rising awareness about early detection, expanding healthcare infrastructure, and growing investments in advanced diagnostic technologies. In addition, supportive government initiatives and an increasing focus on improving patient outcomes further contribute to the rapid market expansion in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Lung Cancer Screening Software Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Lung Cancer Screening Software Market Leaders Operating in the Market Are:

• Koninklijke Philips N.V. (Netherlands)
• Volpara Health Limited (New Zealand)
• Siemens Healthcare GmbH (Germany)
• MeVis Medical Solutions AG (Germany)
• CANON MEDICAL SYSTEMS EUROPE B.V. (U.S.)
• Medtronic (Ireland)
• FUJIFILM Holdings Corporation (Japan)
• Median Technologies (France)
• Aidence (Netherlands)
• Core Talent and Leadership Development Private Limited (South Korea)
• Oncocyte Corporation (U.K.)

Latest Developments in Lung Cancer Screening Software Market

• In November 2023, Aidence, Incepto, and Thirona jointly launched a clinical solution designed to support the expansion of lung cancer screening across Europe. This collaboration marks a strategic initiative to enhance screening capabilities and drive advancements in the detection and management of lung cancer throughout the continent
• In July 2022, GE Healthcare bolstered its position in the healthcare sector with the launch of the Voluson Expert 22, the most advanced ultrasound in its Women’s Health portfolio. Featuring graphic-based beam former technology, this product delivers superior imaging quality and increased flexibility, reinforcing GE Healthcare’s dedication to offering state-of-the-art products and services to healthcare institutions
• In October 2021, Thynk Health announced a strategic partnership with Infervision, leveraging the world's most advanced technologies to fight lung cancer. This collaboration enhances lung cancer screening and strengthens Thynk Health’s market presence, positioning the company as a leading force in pulmonary nodule management and innovative healthcare solutions

SKU-46081